Last reviewed · How we verify
Tritanrix-HepB
Tritanrix-HepB is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b.
Tritanrix-HepB is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Tritanrix-HepB |
|---|---|
| Also known as | DTPw-HBV vaccine, DTPw-HBV |
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against these pathogens, providing long-term immunity. The vaccine contains inactivated or attenuated forms of the pathogens, which are unable to cause disease but still trigger an immune response. This immune response helps the body to recognize and fight off future infections.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b in infants and children
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Vomiting
Key clinical trials
- A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa (PHASE2)
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa (PHASE3)
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |